Despite a sizable financial disadvantage, ST-segment elevation MI (STEMI) patients who could be treated effectively in an intensive or non-intensive care unit fare better in the ICU, according to research published June 4 in The BMJ.

Researchers have identified a new barrier to timely care for MI patients: a perceived inability to act that leaves them immobilized and unable to seek professional help, in some cases for an excess of 24 hours.

Mental health disorders like PTSD and depression might not be as much of a barrier to cardiac rehabilitation as was previously thought, according to a study of more than 85,000 U.S. veterans published in the Journal of the American Heart Association.

An expert consensus document endorsed by four major cardiology societies redefines cardiogenic shock based on patient descriptions, physical markers and a standardized set of vocabulary.

Low-dose daily aspirin may be effective as a preventive therapy for heart patients with symptomatic atherosclerotic disease, but in the general population the drug’s risk of intracranial bleeding outweighs any CV benefits it may have, according to a study published May 13 in JAMA Neurology.

CVD-related fatalities in individuals under 75 years old are on the rise in the U.K. for the first time in five decades, the Guardian reported May 12.

A machine learning algorithm can now predict death and MI more accurately than certified cardiologists, according to research presented at the International Conference on Nuclear Cardiology and Cardiac CT in Lisbon, Portugal, this May.

A new biotech company out of Massachusetts is levering human genetics and genome editing to “turn the tide” of coronary artery disease (CAD), experimenting with CRISPR to stop CAD from ever developing in at-risk individuals.